Skip to content

The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma

The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma: A Multicenter, Prospective, Randomized Trial

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01820884
Acronym
EC-02
Enrollment
240
Registered
2013-03-29
Start date
2012-11-30
Completion date
2026-12-31
Last updated
2024-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Neoplasms

Brief summary

This randomized trial is studying the efficacy and safety of the hysterectomy alone compared with hysterectomy and bilateral salpingo-oophorectomy (BSO) for patients with Stage IA endometrial carcinoma.

Interventions

PROCEDURETH

Total hysterectomy

PROCEDURETH/BSO

Total hysterectomy and bilateral salpingo-oophorectomy

PROCEDUREBPLND

bilateral pelvic and para-aortic lymph node dissection

Sponsors

Shandong University
CollaboratorOTHER
Huazhong University of Science and Technology
CollaboratorOTHER
Zhejiang University
CollaboratorOTHER
Ding Ma
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* FIGO stage: ⅠA, endometrial carcinoma; * Female, Chinese women; * premenopausal women; * ≤ 50 years old; * Pathological diagnosis by curettage/hysteroscopy : G1 * No prior treatment; * Provide written informed consent.

Exclusion criteria

* The suspicious metastasis of ovarian; * Family history of ovarian cancer; * Suffering from other malignancies; * Concurrently participating in other clinical trials; * Unable or unwilling to sign informed consents; * Unable or unwilling to abide by protocol.

Design outcomes

Primary

MeasureTime frame
Disease-free survival (DFS)3-year DFS

Secondary

MeasureTime frameDescription
Clinical gynecologic endocrine function1-year periodTo observe the level of female hormone,i.e., estrogen, FSH, LH
Quality of Life3-year period
Overall Survival (OS)3-year OS

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026